Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DR26FSQN2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,729
Award facts
- Contract value 100% obligated
- $83,728.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $83,728.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. The order was issued on November 18, 2025, with an ultimate completion date of December 10, 2025, under firm fixed-price terms with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to provide comprehensive pharmaceutical sourcing for Department of Defense military healthcare facilities globally.
DMS Pharmaceutical Group has demonstrated substantial contracting capability as a regional prime vendor under the PPV-G GEN V program, which became effective November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The parent Indefinite Delivery Contract encompasses a 30-month base period with three optional 30-month renewal periods and authorizes the issuance of delivery orders for branded and generic prescription medications, biologics, vaccines, and medical consumables. The company's established performance across multiple therapeutic categories, including oncology treatments, immunosuppressants, and specialty pharmaceuticals, supports its role as a critical supplier within the federal military pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FSQN2?
SPE2DR26FSQN2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FSQN2 worth?
The government has obligated $83,729 on SPE2DR26FSQN2.
Is contract SPE2DR26FSQN2 an order under another contract?
Yes. SPE2DR26FSQN2 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQN2 competed?
The extent of competition for SPE2DR26FSQN2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award